Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC)

Hetronifly is the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC (in combination with carboplatin and etoposide). Hetronifly is the only anti-PD-1 mAb approved in Europe for the treatment of ES-SCLC and is already approved in China, and…